Cantargia AB (CANTA) - Total Liabilities

Latest as of September 2025: Skr61.31 Million SEK ≈ $6.60 Million USD

Based on the latest financial reports, Cantargia AB (CANTA) has total liabilities worth Skr61.31 Million SEK (≈ $6.60 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Cantargia AB - Total Liabilities Trend (2011–2024)

This chart illustrates how Cantargia AB's total liabilities have evolved over time, based on quarterly financial data. See Cantargia AB current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Cantargia AB Competitors by Total Liabilities

The table below lists competitors of Cantargia AB ranked by their total liabilities.

Company Country Total Liabilities
Suprema ID Inc
KQ:317770
Korea ₩31.52 Billion
Suzhou QingYue Optoelectronics Technology Co. Ltd. A
SHG:688496
China CN¥695.20 Million
Marchex Inc
NASDAQ:MCHX
USA $9.60 Million
Beijing North Star Company Limited
F:BJ3
Germany €33.63 Billion
PP Properti Tbk PT
JK:PPRO
Indonesia Rp8.01 Trillion
JLS Co.Ltd
KQ:040420
Korea ₩19.77 Billion
SERESCO (ACC.P.DESD.)-16
F:XV7
Germany €25.40 Million
Gentian Diagnostics AS
OL:GENT
Norway Nkr53.58 Million

Liability Composition Analysis (2011–2024)

This chart breaks down Cantargia AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Cantargia AB (CANTA) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 5.82 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.21 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.17 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Cantargia AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Cantargia AB (2011–2024)

The table below shows the annual total liabilities of Cantargia AB from 2011 to 2024.

Year Total Liabilities Change
2024-12-31 Skr54.12 Million
≈ $5.82 Million
-1.54%
2023-12-31 Skr54.97 Million
≈ $5.92 Million
-35.42%
2022-12-31 Skr85.11 Million
≈ $9.16 Million
+26.10%
2021-12-31 Skr67.50 Million
≈ $7.26 Million
+101.02%
2020-12-31 Skr33.58 Million
≈ $3.61 Million
+41.18%
2019-12-31 Skr23.78 Million
≈ $2.56 Million
+45.04%
2018-12-31 Skr16.40 Million
≈ $1.76 Million
-42.12%
2017-12-31 Skr28.33 Million
≈ $3.05 Million
+172.85%
2016-12-31 Skr10.38 Million
≈ $1.12 Million
+212.02%
2015-12-31 Skr3.33 Million
≈ $358.15K
-79.24%
2014-12-31 Skr16.03 Million
≈ $1.73 Million
+1768.34%
2013-12-31 Skr858.07K
≈ $92.34K
+23.05%
2012-12-31 Skr697.32K
≈ $75.04K
-19.04%
2011-12-31 Skr861.27K
≈ $92.69K
--

About Cantargia AB

ST:CANTA Sweden Biotechnology
Market Cap
$57.84 Million
Skr537.50 Million SEK
Market Cap Rank
#21404 Global
#390 in Sweden
Share Price
Skr2.16
Change (1 day)
+0.56%
52-Week Range
Skr1.13 - Skr6.20
All Time High
Skr58.00
About

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which… Read more